<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Non-access-related infections in patients on chronic dialysis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Non-access-related infections in patients on chronic dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Non-access-related infections in patients on chronic dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca J Schmidt, DO, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer E Flythe, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In addition to infections associated with dialysis access devices, patients with end-stage kidney disease (ESKD) who require kidney replacement therapy may be susceptible to non-access-related infections. Diagnostic strategies for these infections are similar to those used for patients without kidney disease. However, a higher index of suspicion and a lower threshold for the initiation of a search are appropriate since patients with ESKD are frequently diabetic and/or immunosuppressed because of the retention of uremic toxins. Careful attention to appropriate dosing of antibiotics and the avoidance (if possible) of nephrotoxic drugs in the patient with residual kidney function are also significant issues.</p><p>Many of the infections reviewed in this topic are not unique to the patient on dialysis. As a result, although the likelihood of their occurrence may be increased, special considerations and guidelines for the patient on dialysis are not available. Diagnostic and treatment strategies must be tailored to the individual patient, including the consequences of kidney disease and other comorbid conditions, the geographic location, and specific environmental exposures.</p><p>A review of the clinical characteristics of infections not related to the dialysis access is presented here. Reviews of access-related infections and the clinical manifestations and treatment of sepsis in patients on dialysis, a complication most commonly due to infection of dialysis access devices, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1888.html" rel="external">"Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults", section on 'Catheter-related infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Data from the United States Renal Data System (USRDS) indicate that infections are a leading cause of death among patients with end-stage kidney disease (ESKD) [<a href="#rid1">1,2</a>], accounting for approximately 10 to 13 percent of all deaths in 2018 [<a href="#rid3">3-5</a>]. The proportion of deaths due to infection increased with the advent of coronavirus disease 2019 (COVID-19). For example, in patients on peritoneal dialysis in 2020, infections caused nearly 17 percent of fatalities, and COVID-19 was the fourth leading cause of death, at over five percent [<a href="#rid6">6</a>]. Infections are the leading cause of hospitalizations among patients treated with peritoneal dialysis and have been the second leading cause, behind cardiovascular disease, of hospitalizations among patients treated with hemodialysis. However, in 2020, driven by COVID-19, hospitalizations for infectious causes surpassed those for cardiac causes in the hemodialysis population [<a href="#rid7">7</a>]. </p><p>Compared with the population with normal kidney function, patients with chronic kidney disease (CKD) and ESKD are at higher risk of contracting bacterial infections, particularly urinary tract infections, pneumonia, and sepsis [<a href="#rid8">8-11</a>]. They are also more likely to have an infection at the time of hospitalization [<a href="#rid12">12</a>].</p><p>Because of their propensity for causing sepsis, infections related to dialysis access devices are potentially catastrophic [<a href="#rid13">13,14</a>]. The annual mortality secondary to sepsis is 100- to 300-fold higher in patients on dialysis [<a href="#rid13">13</a>] (see  <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults", section on 'Catheter-related infection'</a>). In addition, a prospective study evaluating the outcome of 65 episodes of <em>Staphylococcus aureus</em> bacteremia in patients on hemodialysis (89 percent of which were due to an access) found that metastatic complications and death occurred in 44 and 14 percent of patients, respectively. In contrast, other studies suggest that non-access-related infections are less common and not as devastating, accounting for an overall mortality rate of less than 3 percent [<a href="#rid15">15</a>].</p><p>Patients on dialysis are at a higher risk for acquiring infection caused by multidrug-resistant organisms and for death resulting from infection [<a href="#rid16">16</a>]. This is because of their likelihood of requiring treatment that involves invasive devices, their frequent exposure to antibiotics, and their altered immunity [<a href="#rid17">17</a>]. As reported by the USRDS, death due to infection in patients over the age of 65 years is approximately twice that of younger patients [<a href="#rid3">3</a>]. Smoking has been shown to be an important risk factor for infection-related morbidity and mortality among patients on hemodialysis [<a href="#rid18">18</a>].</p><p>Among patients undergoing chronic kidney replacement therapy, the most important sites of infection not related to the dialysis access include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Upper and lower respiratory tract</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal tract (eg, hepatitis and <em>Clostridioides</em> <em>difficile</em> colitis)</p><p class="bulletIndent1"><span class="glyph">●</span>Genitourinary tract</p><p class="bulletIndent1"><span class="glyph">●</span>Skin and bone (eg, cellulitis and osteomyelitis)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">RESPIRATORY SYSTEM</span><span class="headingEndMark"> — </span>Respiratory tract infections in patients on dialysis may be community or hospital acquired. As previously mentioned, respiratory infections are the second leading cause of infection-related deaths.</p><p class="headingAnchor" id="H4"><span class="h2">Upper respiratory tract</span><span class="headingEndMark"> — </span>Compared with the general population, patients with end-stage kidney disease (ESKD) are not overly susceptible to sinusitis, rhinitis, or pharyngitis. Diagnoses and treatments are therefore similar to those for the general population. However, special attention must be given to accurate drug dosing and the loss of antibiotics across the dialysis membrane among those undergoing hemodialysis. (See  <a class="medical medical_review" href="/z/d/html/7533.html" rel="external">"An overview of rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Lower respiratory tract</span><span class="headingEndMark"> — </span>Bronchitis and pneumonia are common in patients on dialysis. In one retrospective study of patients on dialysis, the probability of being hospitalized from pneumonia was 9 and 36 percent at one and five years, respectively [<a href="#rid19">19</a>]. A subsequent observational study found a pneumonia incidence rate of 21.4 events/100 patient-years, with 90.1 percent requiring hospitalization, and a 30-day fatality of 10.7 percent in Medicare patients on dialysis [<a href="#rid20">20</a>]. Significantly higher hospitalizations also occurred in the 12 months following the pneumonia episode, increasing the overall costs [<a href="#rid20">20</a>].</p><p>Pneumonia is an important cause of death and hospitalization in patients, carrying significant risk for those with advanced chronic kidney disease (CKD) [<a href="#rid21">21</a>]. Compared with the population with normal kidney function, the rate of pneumonia is three times greater in those with CKD and five times greater in those with ESKD [<a href="#rid8">8</a>]. One-in-five patients with ESKD developed pneumonia during their first year on dialysis, and 42 percent of these required hospitalization [<a href="#rid22">22</a>]. The lengths of hospitalization in CKD and ESKD patients with pneumonia are similar and are four to six times longer than the non-CKD population [<a href="#rid8">8</a>].</p><p>A retrospective study of the bacteriology and outcomes of empyema in 84 patients with stage 4 CKD and 40 patients with ESKD found that most empyemas were secondary to pneumonia. Gram-negative organisms were cultured in 67 percent of patients with stage 4 CKD (34 percent were <em>Klebsiella pneumoniae</em>), but aerobic gram-positive organisms predominated in the patients with ESKD (54 percent, with 67 percent of those <em>S. aureus</em>) [<a href="#rid23">23</a>]. Compared with the patients with stage 4 CKD, patients with ESKD had a higher catheter-associated infection rate and lower infection-associated mortality [<a href="#rid23">23</a>].</p><p>Compared with patients without kidney disease, bronchitis and pneumonia may be more difficult to diagnose since pulmonary fluid fluctuates markedly with dialysis treatments. Nevertheless, the presence of a productive cough, fever, chills, pleuritic pain, and/or dyspnea suggest an infectious pulmonary process. The diagnosis may be confirmed by sputum evaluation and chest radiograph. Treatment should not be withheld if a high index of suspicion remains, despite the absence of diagnostic test results. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7022.html" rel="external">"Community-acquired pneumonia in adults: Assessing severity and determining the appropriate site of care"</a> and  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a>.)</p><p class="headingAnchor" id="H3767018993"><span class="h2">COVID-19</span><span class="headingEndMark"> — </span>Patients with ESKD have been disproportionately impacted by the COVID-19 pandemic. COVID-19 in patients with ESKD is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/130632.html" rel="external">"COVID-19: Issues related to end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">HUMAN IMMUNODEFICIENCY VIRUS INFECTION</span><span class="headingEndMark"> — </span>In early studies, survival on dialysis was short in most patients with acquired immune deficiency syndrome (AIDS; only a few months), although some asymptomatic patients or those with early AIDS survived for one to two years. Subsequent studies, however, have noted prolonged survival in infected patients requiring kidney replacement therapy. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1915.html" rel="external">"Human immunodeficiency virus and dialysis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">NERVOUS SYSTEM</span><span class="headingEndMark"> — </span>Meningitis and infections of the brain parenchyma should be considered in patients on dialysis with fever and/or central nervous system symptoms or findings. An increased risk of central nervous system infection and related mortality has been reported for patients on dialysis [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H8"><span class="h2">Meningitis</span><span class="headingEndMark"> — </span>A paucity of literature exists concerning the incidence of meningitis in patients on dialysis. <em>Streptococcus meningitis</em>, an uncommon infection in all adults, was reported as a complication of peritonitis in one patient on peritoneal dialysis [<a href="#rid25">25</a>]. </p><p>Fungal meningitis has also been reported in patients with end-stage kidney disease (ESKD). Cryptococcal meningoencephalitis, the most frequent manifestation of cryptococcal infection, has been noted with increased frequency among the general patient population because of human immunodeficiency virus (HIV) infection. Involvement of the meninges with <em>Cryptococcus</em> in patients on peritoneal dialysis most commonly results from systemic disease initially arising from infection of the peritoneum [<a href="#rid26">26-28</a>]. (See  <a class="medical medical_review" href="/z/d/html/2447.html" rel="external">"Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV"</a>.)</p><p class="headingAnchor" id="H163926816"><span class="h2">Herpes zoster</span><span class="headingEndMark"> — </span>Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles) (see  <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Risk factors'</a>). </p><p>Chronic kidney disease (CKD) is a risk factor for the development of herpes zoster [<a href="#rid29">29-31</a>]. In one study, compared with patients without ESKD, patients with ESKD on hemodialysis had twice the risk of zoster by 4.7 years of follow-up (adjusted hazard ratio 1.98, 95% CI 1.72-2.27) [<a href="#rid30">30</a>]. Vaccination against herpes zoster for patients with ESKD is discussed at length elsewhere [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/1963.html" rel="external">"Immunizations in patients with end-stage kidney disease", section on 'Varicella-zoster virus vaccine'</a>.)</p><p>Treatment with antiviral agents such as <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> requires adjustment in dose for patients on dialysis.</p><p class="headingAnchor" id="H9"><span class="h2">Mucormycosis</span><span class="headingEndMark"> — </span>Mucormycosis, a life-threatening fungal disease, is characterized by fungal sinusitis with invasion of adjacent structures, including the brain. It most commonly occurs in immunocompromised and diabetic patients and patients on dialysis treated with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a>. The fungal infection may be contracted from the environment and then disseminate, frequently affecting the central nervous system and sinuses (rhinocerebral mucor). (See  <a class="medical medical_review" href="/z/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a>.)</p><p>Patients on hemodialysis in whom aluminum chelation therapy with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> has been administered at relatively high doses appear to be at significant risk for mucormycosis. Presenting forms of the infection most commonly include rhinocerebral and disseminated disease (31 and 44 percent, respectively). (See  <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>.)</p><p>Mucormycosis infecting the peritoneum has also been reported in patients on peritoneal dialysis. In one case report, <em>Rhizopus</em> species grew from cultures obtained from a patient with clinical signs of peritonitis [<a href="#rid33">33</a>]. The patient had no known risk factor for the infection.</p><p>The management of these fungal infections is discussed in the appropriate topic reviews.</p><p class="headingAnchor" id="H10"><span class="h1">GASTROINTESTINAL SYSTEM</span></p><p class="headingAnchor" id="H11"><span class="h2">Gallbladder and biliary disease</span><span class="headingEndMark"> — </span>A paucity of literature exists concerning the prevalence of cholecystitis and cholecystolithiasis in patients with end-stage kidney disease (ESKD). In an observational study of 179 patients with ESKD who presented to the emergency department with abdominal pain, approximately 6 percent were diagnosed with cholecystitis or biliary colic [<a href="#rid34">34</a>]. </p><p>The prevalence of cholecystolithiasis in patients with ESKD may be comparable to that in the general population. In one ultrasonographic study, no significant difference was observed in the prevalence of cholecystolithiasis in 73 patients on hemodialysis and a control group (16 and 23 percent, respectively) [<a href="#rid35">35</a>]. A case report of emphysematous cholecystitis in a patient on peritoneal dialysis suggests that ischemia may play a role in the development of this entity [<a href="#rid36">36</a>].</p><p>Common bile duct dilatation may occur more commonly among patients with kidney disease due to polycystic kidney disease compared with those without the disorder. In one study, for example, 22 of 55 patients (40 percent) with polycystic kidney disease and varying levels of kidney function were found to have biliary dilatation measuring at least 7 millimeters compared with 5 of 55 controls (9.1 percent) matched for age, sex, kidney function, and duration of dialysis [<a href="#rid37">37</a>]. Whether this is associated with an enhanced risk of biliary infection and/or pathology is unknown.</p><p>The clinical presentation and overall management of patients on dialysis with cholecystitis are similar to those without kidney disease. (See  <a class="medical medical_review" href="/z/d/html/666.html" rel="external">"Acute calculous cholecystitis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3684.html" rel="external">"Treatment of acute calculous cholecystitis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Visceral leakage causing peritonitis</span><span class="headingEndMark"> — </span>Peritonitis is a common complication in patients undergoing peritoneal dialysis. Although associated with significant morbidity, it is usually easily treatable (see  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>). However, peritonitis resulting from enteric bacteria is frequently caused by injury to gastrointestinal viscera and may have devastating consequences. Peritonitis acquired by virtue of microscopic perforation may be insidious, with subtle or no radiographic abnormalities despite evolving clinical symptoms. In a review of 230 patients on peritoneal dialysis followed over eight years, approximately 30 percent of peritonitis episodes resulting from enteric organisms were due to documented visceral leakage, including cholecystitis, ischemic bowel disease, viscus perforation, or diverticulitis [<a href="#rid38">38</a>]. Among these 26 patients with visceral disease, 50 percent died, and 30 percent switched to hemodialysis.</p><p class="headingAnchor" id="H13"><span class="h2"><i>Helicobacter pylori</i> infection</span><span class="headingEndMark"> — </span>The literature is limited with regard to the prevalence of gastroduodenal <em>Helicobacter pylori</em> infection in patients on dialysis. In a study of over 1200 patients with ESKD who underwent an upper endoscopy for transplant evaluation, <em>H. pylori</em> was detected in approximately one-third of the patients [<a href="#rid39">39</a>]. In another study of patients on dialysis, <em>H. pylori</em> was detected by enzyme-linked immunosorbent assay (ELISA) in 33 percent [<a href="#rid40">40</a>]. The prevalence, diagnosis, and management of <em>H. pylori</em> infection in patients on dialysis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1897.html" rel="external">"Unique aspects of gastrointestinal disease in patients on dialysis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>Infectious hepatitis, particularly with hepatitis B and C, is a significant cause of morbidity and mortality in patients on hemodialysis, with hepatitis C being a leading cause of liver disease. Fortunately, the incidence of both hepatitis B and C infections is declining in this patient population.</p><p>Discussions concerning the epidemiology, diagnosis, and treatment of hepatitis B and C infections in patients with and without kidney disease are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1861.html" rel="external">"Hepatitis C virus infection in patients on maintenance dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1931.html" rel="external">"Hepatitis B virus and dialysis patients"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Gastroenteritis</span><span class="headingEndMark"> — </span>Patients with ESKD are susceptible to the same viral gastroenteritides as the general population, although their ability to combat such illnesses may be suppressed. An important issue in patients on dialysis with significant gastrointestinal fluid loss (by vomiting and/or diarrhea) is the accurate assessment of intravascular volume to avoid a substantial decrease in the effective circulating volume with dialysis therapy. Careful attention must therefore be given to variations in blood pressure during the procedure and the accurate determination of dry weight. Acute symptomatic relief may be obtained with the administration of an antidiarrheal agent, such as <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> given at a dose of 2 to 4 mg by mouth (PO) initially then 2 mg after each unformed stool up to 10 to 12 mg daily.</p><p class="headingAnchor" id="H16"><span class="h2">Diverticulitis</span><span class="headingEndMark"> — </span>Patients on dialysis develop diverticulitis at least as frequently as patients not on dialysis. An increased incidence is observed in patients with polycystic kidney disease since a majority of such individuals who require dialysis have diverticula. (See  <a class="medical medical_review" href="/z/d/html/1679.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Extrarenal manifestations"</a>.)</p><p>The presentation of diverticulitis in the chronically ill patient on dialysis may be more insidious than that of the patient without kidney disease. The typical clinical manifestations of a patient presenting with acute diverticulitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2633.html" rel="external">"Clinical manifestations and diagnosis of acute colonic diverticulitis in adults", section on 'Clinical manifestations'</a>.) </p><p>Management must be individualized but is essentially similar to that for patients not on dialysis (see  <a class="medical medical_review" href="/z/d/html/1380.html" rel="external">"Acute colonic diverticulitis: Medical management"</a>). Nonoperative management may be preferred for patients with ESKD who have acute diverticulitis. In one study of 962 patients with ESKD and matched controls &gt;65 years of age who underwent surgical intervention for diverticulitis, those with ESKD had a higher rate of in-hospital mortality and postoperative complications compared with those without ESKD [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H17"><span class="h2"><i>Clostridioides difficile</i> colitis</span><span class="headingEndMark"> — </span>Patients on dialysis are particularly susceptible to <em>C. difficile</em> colitis since they are commonly administered antibiotics. Patients on maintenance hemodialysis are more than four times as likely to develop <em>C. difficile</em> infection than individuals not on dialysis [<a href="#rid42">42</a>]. In one study of 62 patients on dialysis and 8 individuals with acute kidney disease, 110 episodes of <em>C. difficile</em> colitis reportedly occurred over a two-year period [<a href="#rid43">43</a>]. In this cohort, infection was associated with a dismal long-term prognosis: 60 of 70 patients died over a follow-up period of five years. The rate of <em>C. difficile</em> was 1.05 per 100 dialysis patient years in a United Kingdom registry [<a href="#rid10">10</a>]. Colonization with toxigenic <em>C. difficile</em> was higher among patients with chronic kidney disease (CKD) in Australia with a relative risk (RR) of 5.78 (95% CI 2.29-14.59) [<a href="#rid44">44</a>]. </p><p>Another study found that the incidence of <em>C. difficile</em>–associated infection was 10.7 per 1000 admissions for patients with CKD compared with 2.7 per 1000 among other patients (p&lt;0.0001) [<a href="#rid45">45</a>]. In this study, symptoms in patients with CKD included diarrhea (89 percent), fever (53 percent), and ileus or abdominal pain (44 percent). ESKD and being on dialysis, as opposed to CKD stages 3 to 5, appears to be a risk factor for <em>C. difficile</em> colitis for unclear reasons [<a href="#rid46">46,47</a>]. A subsequent retrospective review of <em>C. difficile</em> infections in patients with CKD again showed those on dialysis to be twice as likely to develop <em>C. difficile</em> infections than patients without CKD and 1.33 times more likely than patients with nondialysis CKD [<a href="#rid48">48</a>]. Interestingly, patients on dialysis with <em>C. difficile</em> infection had fewer complications from the infection (colectomy, longer hospitalization, discharge to a health care facility) than those with CKD not on dialysis [<a href="#rid48">48</a>]. A meta-analysis examining 19 studies with 116,875 patients found a higher relative risk of recurrent <em>C.</em> <em>difficile</em> infection (pooled RR 2.73, 95% CI 1.36-5.47), as well as higher mortality in ESKD and CKD patients (RR 1.76, 95% CI 1.32-2.34) [<a href="#rid49">49</a>].</p><p>A review of 419,875 patients on incident dialysis in United States Renal Data System (USRDS) data from 2005 to 2008 found 4.25 percent of patients diagnosed with <em>C. difficile</em> infection [<a href="#rid50">50</a>]. Most had either a hospital or intensive care unit (ICU) stay within 90 days. Risk factors for <em>C. difficile</em> infection included age ≥65 years of age (RR 1.76), human immunodeficiency virus (HIV; RR 2.68), and a history of bacteremia (RR 1.74). The relative risk of death was higher in those with cirrhosis (RR 1.76) and those older than 65 years of age (RR 2.28). Recurrent <em>C. difficile</em> occurred in 23.6 percent, more commonly in White Americans [<a href="#rid50">50</a>].</p><p>Management of <em>C. difficile</em> colitis in patients on dialysis is similar to the regimen used in patients not on dialysis but with minor dosing adjustments [<a href="#rid51">51</a>]. It is recommended that patients on dialysis with estimated glomerular filtration rates of less than 10 mL/min receive a 50 percent dose reduction of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid52">52</a>]; the drug should be administered after hemodialysis [<a href="#rid52">52</a>] (see  <a class="medical medical_review" href="/z/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>). The rise in cases of <em>C. difficile</em> has been accompanied by a resistance to treatment. This has led to the development of alternative treatment strategies for resistant cases. (See  <a class="medical medical_review" href="/z/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">GENITOURINARY INFECTION</span><span class="headingEndMark"> — </span>Urinary tract infections associated with urinary catheterization are among the most common nosocomial infections among hospitalized patients on chronic dialysis [<a href="#rid53">53</a>]. The clinical presentation of urinary tract infection in a patient on dialysis with residual urine production is similar to that of an individual without kidney disease. By comparison, anuric patients may present with only bladder discomfort and/or fever.</p><p class="headingAnchor" id="H1621801539"><span class="h2">High rates of asymptomatic pyuria and bacteriuria</span><span class="headingEndMark"> — </span>Among asymptomatic patients on dialysis, the presence of pyuria, with or without bacteriuria, is common [<a href="#rid54">54-59</a>]. With few exceptions, we generally do not treat asymptomatic patients who have pyuria and/or bacteriuria. (See  <a class="medical medical_review" href="/z/d/html/8061.html" rel="external">"Asymptomatic bacteriuria in adults"</a>.)</p><p>In a study that included 70 asymptomatic patients on hemodialysis, 36 patients (51 percent) had pyuria [<a href="#rid59">59</a>]. In another study of 43 asymptomatic patients on peritoneal dialysis, 12 (28 percent) had pyuria [<a href="#rid57">57</a>]. The reported prevalence of bacteriuria among asymptomatic patients on dialysis who have pyuria is variable, ranging between 11 and 70 percent [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Cystitis</span><span class="headingEndMark"> — </span>Anuric patients with acute simple cystitis may present with only bladder symptoms (ie, suprapubic discomfort). Management of symptomatic simple cystitis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females"</a> and  <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">"Acute simple cystitis in adult and adolescent males"</a>.)</p><p>Pyocystis, defined as a large collection of pus in a nonfunctioning bladder, may occur in anuric patients on dialysis; it is an overlooked cause of fever in this patient population. In this setting, culture most commonly yields multiple organisms. Treatment usually consists of bladder irrigation with antimicrobial solutions and possibly antimicrobial therapy, depending upon the virulence of the pathogen and the clinical state of the patient.</p><p class="headingAnchor" id="H21"><span class="h2">Pyelonephritis</span><span class="headingEndMark"> — </span>The presentation of pyelonephritis in the patient with and without kidney disease is similar; symptoms or signs may include fever, abdominal pain, dysuria (if not anuric), and flank pain. Patients with end-stage kidney disease (ESKD) due to polycystic kidneys and/or older patients on dialysis may be at increased risk. (See  <a class="medical medical_review" href="/z/d/html/1676.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Evaluation and management of complicated urinary tract infections"</a>.)</p><p>Treatment of the patient with pyelonephritis is based upon the clinical characteristics of the patient and microbiologic results (see  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>). The treatment of kidney infection in the patient with polycystic kidneys is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1676.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Evaluation and management of complicated urinary tract infections"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SKIN AND BONE INFECTIONS</span><span class="headingEndMark"> — </span>Cellulitis and osteomyelitis are significant causes of morbidity in patients on dialysis.</p><p class="headingAnchor" id="H23"><span class="h2">Cellulitis</span><span class="headingEndMark"> — </span>Cellulitis frequently occurs in the patient with diabetes on dialysis with neurologic and peripheral vascular disease and is an important cause of morbidity in patients on dialysis. Diabetic foot infection poses a serious risk for amputation and must be promptly identified and treated (see  <a class="medical medical_review" href="/z/d/html/8175.html" rel="external">"Management of diabetic foot ulcers"</a>). The duration of treatment among these patients is often longer than for immunocompetent nondialysis patients. (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.) </p><p class="headingAnchor" id="H24"><span class="h2">Osteomyelitis</span><span class="headingEndMark"> — </span>Osteomyelitis may result from direct extension of cellulitis, which, as mentioned, is a common occurrence in diabetics, and via hematogenous spread caused by the failure to recognize and remove infected central venous hemodialysis catheters and/or chronic access. A high index of suspicion is therefore appropriate in patients on dialysis, particularly those with diabetes (see  <a class="medical medical_review" href="/z/d/html/7653.html" rel="external">"Approach to imaging modalities in the setting of suspected nonvertebral osteomyelitis"</a>). As with patients not on dialysis, treatment is based upon cultured pathogens (when available) and/or empiric regimens. (See  <a class="medical medical_review" href="/z/d/html/7668.html" rel="external">"Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Infection and calciphylaxis</span><span class="headingEndMark"> — </span>Calciphylaxis, a rare complication of the skin microvasculature, affects an estimated 1 percent of patients with end-stage kidney disease (ESKD) per year (see  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a>). This disorder is associated with extensive microvascular calcification and occlusion with thrombosis of the skin, thereby resulting in characteristic violaceous skin lesions. Progression to nonhealing ulcers and sepsis is confounded by secondary infection, which also leads to bloodborne infection and often death [<a href="#rid60">60,61</a>].</p><p class="headingAnchor" id="H26"><span class="h1">METHICILLIN-RESISTANT <i>STAPHYLOCOCCUS AUREUS</i></span><span class="headingEndMark"> — </span><em>S. aureus</em> bacteremia is common in patients on hemodialysis, with nearly 40 percent of these infections being methicillin resistant (MRSA) [<a href="#rid62">62</a>]. <em>S. aureus</em> bacteremia is usually related to the presence of an indwelling dialysis catheter or arteriovenous graft and/or peritonitis. The widespread use of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> in patients on dialysis is due to the convenience of infrequent dosing related to hemodialysis treatments and the recognition that <em>Staphylococcus</em> species cultured from these populations is often resistant to methicillin [<a href="#rid63">63</a>]. In 2005, the incidence of invasive MRSA infection was 45.2 cases per 1000 patients on dialysis compared with a rate of 0.2 to 0.4 cases per 1000 in the general population [<a href="#rid10">10,64,65</a>].</p><p>Many <em>Staphylococcus</em> infections in patients on peritoneal dialysis are actually <em>Staphylococcus epidermidis</em>; this is a less virulent pathogen but one that is also often resistant to methicillin (MRSE). Because <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> has been widely used as empiric therapy for the past decade, there is concern about the enhanced incidence of infection resulting from vancomycin-resistant <em>Enterococcus</em> (VRE) [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">VANCOMYCIN-RESISTANT <i>ENTEROCOCCUS</i></span><span class="headingEndMark"> — </span>The emergence of vancomycin-resistant <em>Enterococcus</em> (VRE) and the rising incidence of VRE infection/colonization pose significant health care risks:</p><p class="bulletIndent1"><span class="glyph">●</span>Colonization of this organism can evolve into serious infection.</p><p class="bulletIndent1"><span class="glyph">●</span>Resistance may be passed to more virulent organisms such as <em>S. aureus</em>.</p><p class="bulletIndent1"><span class="glyph">●</span>The carriage of VRE may render the patient on dialysis unacceptable for kidney transplantation.</p><p></p><p>VRE bacteremia predominantly affects severely ill patients who have previously received extensive antibiotic therapy [<a href="#rid67">67</a>]. Patients on dialysis, with their propensity for access infection and comorbid conditions requiring prolonged hospitalization, are particularly at risk; however, dialysis vintage has not been found to correlate with the presence of VRE, nor has an increased risk of death been observed in VRE-positive patients [<a href="#rid68">68</a>].</p><p>In a meta-analysis of observational studies including nearly 5000 patients on dialysis, approximately 6 percent were found to be colonized with VRE [<a href="#rid69">69</a>]. Risk factors for VRE colonization included hospitalization in the recent past and prior use of antibiotics. Patients colonized with VRE had a higher risk of infection with VRE (odds ratio 21.6, 95% CI 5.3-81.6). </p><p>Centers for Disease Control and Prevention (CDC) guidelines mandate that VRE-positive patients on hemodialysis must be isolated during treatment and hospitalizations [<a href="#rid70">70,71</a>]. The acquisition of VRE is also of particular concern among patients on peritoneal dialysis. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a>, an antimicrobial used in the treatment of VRE infections, is not well suited as long-term therapy, because myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) can develop in patients receiving linezolid for more than two weeks. Such adverse hematologic effects may be more common in patients on dialysis. As an example, in a retrospective case-control study, patients with ESKD, compared with those without kidney disease, had a significantly higher rate of linezolid-associated thrombocytopenia (79 versus 43 percent) and anemia (72 versus 37 percent) [<a href="#rid72">72</a>].</p><p>The treatment of VRE is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections"</a>.)</p><p class="headingAnchor" id="H3694169273"><span class="h1">ENDOCARDITIS</span><span class="headingEndMark"> — </span>The major ESKD-specific management issue surrounding infective endocarditis is dialysis access. In patients with a hemodialysis catheter who develop infective endocarditis, catheter removal is warranted. In rare cases, excision of an arteriovenous fistula or graft may be required. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">"Overview of management of infective endocarditis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">TUBERCULOSIS</span><span class="headingEndMark"> — </span>Although the incidence of tuberculosis in patients undergoing dialysis is considered to be relatively low, it appears that patients on dialysis have an enhanced risk for developing tuberculosis. Studies in the United States have reported a 12-fold increased risk of tuberculosis among patients with ESKD compared with the general population [<a href="#rid73">73</a>]. Outside of the United States, a fourfold increase in tuberculosis rates among patients with ESKD has been reported [<a href="#rid73">73</a>]. The prognosis of patients with ESKD who have tuberculosis is uncertain. Some studies suggest that with appropriate treatment the prognosis may be comparable to that of patients without ESKD [<a href="#rid74">74-76</a>]. However, in another study, ESKD was associated with an increased risk of death in older patients with tuberculosis, with a 32.7 percent mortality [<a href="#rid77">77</a>]. Other than attention to appropriate dosing regimens for those with ESKD, the treatment of tuberculosis for patients on dialysis is the same as that for patients not on dialysis. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p>There is a heightened awareness of the propensity for immunosuppressed patients, including those on dialysis, to reactivate old or acquire new tuberculosis infections. In a single dialysis center, for example, one infected health care worker apparently transmitted tuberculosis to 29 patients [<a href="#rid78">78</a>].</p><p>Affected patients frequently present with fever, anorexia, and weight loss [<a href="#rid79">79</a>]. Involvement of extrapulmonary organs is also common, particularly the lymphatic system and peritoneum [<a href="#rid80">80-82</a>].</p><p>Since approximately 30 to 40 percent or more of patients on hemodialysis are anergic, additional clinical testing for the presence of tuberculosis may be appropriate in patients for whom the index of suspicion is high [<a href="#rid83">83-89</a>]. The interferon (IFN)-gamma release assay (IGRA) is generally preferred, over tuberculin skin testing, for diagnosis of latent tuberculosis in patients with ESKD [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p class="headingAnchor" id="H1311839612"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H2614690"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Infections are a leading cause of death among patients with end-stage kidney disease (ESKD), accounting for approximately nearly 17 percent of all fatalities. Access-related infections are the most common and respiratory tract infections are the second most common causes of infection-related deaths. Others include human immunodeficiency virus (HIV) infection, infections of the central nervous system, gastrointestinal tract, genitourinary tract, skin (cellulitis), and bone (osteomyelitis). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucormycosis</strong> – Patients on dialysis treated with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> are at increased risk of mucormycosis, a life-threatening fungal disease that most commonly occurs in immunocompromised and diabetic patients. (See <a class="local">'Mucormycosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peritonitis</strong> – Peritonitis is common in patients undergoing peritoneal dialysis but is usually easily treatable. Peritonitis caused by enteric bacteria is frequently caused by injury to gastrointestinal viscera and may have devastating consequences. (See <a class="local">'Visceral leakage causing peritonitis'</a> above and  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis</strong> – Infectious hepatitis, particularly with hepatitis B and C, is a significant cause of morbidity and mortality in patients on hemodialysis, with hepatitis C being a leading cause of liver disease. The incidence of both hepatitis B and C infections is declining in this patient population. (See <a class="local">'Hepatitis'</a> above and  <a class="medical medical_review" href="/z/d/html/1861.html" rel="external">"Hepatitis C virus infection in patients on maintenance dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1931.html" rel="external">"Hepatitis B virus and dialysis patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Clostridioides</em></strong><strong> </strong><strong><em>difficile</em></strong><strong> colitis</strong> – Patients on dialysis are particularly susceptible to <em>C.</em> <em>difficile</em> colitis since they are commonly administered antibiotics. Mortality and recurrent infections are more common in patients with ESKD than others with <em>C.</em> <em>difficile</em> colitis. Management of <em>C. difficile</em> colitis in patients on dialysis is similar to the regimen used in patients not on dialysis but with dosing adjustments. (See <a class="local">'Clostridioides difficile colitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary tract infection</strong> – Urinary tract infections are the most common nosocomial infections among hospitalized patients on chronic dialysis who have undergone urinary catheterization. <em>Candida</em> is the most frequently observed pathogen. The management of symptomatic urinary tract infection must be tailored to the individual patient on dialysis and the cultured organism. (See <a class="local">'Genitourinary infection'</a> above and  <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin and bone infections</strong> – Cellulitis is common in the patient with diabetes on dialysis with neurologic and peripheral vascular disease and poses risk for complications, including amputation. Osteomyelitis may result from direct extension of cellulitis or via hematogenous spread from an infected central venous hemodialysis catheter and/or chronic access. (See <a class="local">'Skin and bone infections'</a> above and  <a class="medical medical_review" href="/z/d/html/7653.html" rel="external">"Approach to imaging modalities in the setting of suspected nonvertebral osteomyelitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methicillin-resistant </strong><strong><em>Staphylococcus aureus</em></strong> – <em>S. aureus</em> bacteremia is common in patients on hemodialysis and is usually related to the presence of an indwelling dialysis catheter or arteriovenous graft and/or peritonitis. Invasive methicillin-resistant <em>S. aureus</em> (MRSA) infection is more common in the hemodialysis population compared with the general population. (See <a class="local">'Methicillin-resistant staphylococcus aureus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vancomycin-resistant </strong><strong><em>Enterococcus</em></strong> – Vancomycin-resistant <em>Enterococcus</em> (VRE) colonization is not common among hemodialysis outpatients. Centers for Disease Control and Prevention (CDC) guidelines mandate that VRE-positive patients on hemodialysis must be isolated during treatment and hospitalizations. The carriage of VRE may render the patient on dialysis unacceptable for kidney transplantation. (See <a class="local">'Vancomycin-resistant enterococcus'</a> above and  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis</strong> – Patients on dialysis have an enhanced risk for developing tuberculosis. Other than attention to appropriate dosing regimens for those with ESKD, the treatment of tuberculosis in patients on dialysis is the same as that for patients not on dialysis. (See <a class="local">'Tuberculosis'</a> above and  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes zoster</strong> – Herpes zoster is more common in patients on hemodialysis than in the general population and vaccination is recommended. Treatment with antiviral agents such as <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> requires adjustment in dose for patients on dialysis. (See <a class="local">'Herpes zoster'</a> above.)</p><p></p><p class="headingAnchor" id="H1733270892"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jean L Holley, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 55(Suppl 1):S1.</a></li><li class="breakAll">United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2016.</li><li><a class="nounderline abstract_t">Survival, mortality, &amp; causes of death. USRDS. United States Renal Data System. Am J Kidney Dis 2001; 38:S135.</a></li><li class="breakAll">United States Renal Data System. USRDS 2018 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, editor,  National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2018. https://www.usrds.org/2014/view/.</li><li class="breakAll">United States Renal Data System. USRDS 2020 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2020.</li><li class="breakAll">United States Renal Data System 2022 Annual Data Report. End Stage Renal Disease: Chapter 6 Mortality. Available at: https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/6-mortality.</li><li class="breakAll">United States Renal Data System 2022 Annual Data Report. End Stage Renal Disease: Chapter 5 Hospitalization. Available at: https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/5-hospitalization.</li><li><a class="nounderline abstract_t">Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13:199.</a></li><li><a class="nounderline abstract_t">Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59:356.</a></li><li><a class="nounderline abstract_t">Evans R, Caskey F, Fluck R, et al. UK Renal Registry 18th Annual Report: Chapter 12 Epidemiology of Reported Infections amongst Patients Receiving Dialysis for Established Renal Failure in England 2013 to 2014: a Joint Report from Public Health England and the UK Renal Registry. Nephron 2016; 132 Suppl 1:279.</a></li><li><a class="nounderline abstract_t">Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol 2019; 23:437.</a></li><li><a class="nounderline abstract_t">Ishigami J, Grams ME, Chang AR, et al. CKD and Risk for Hospitalization With Infection: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2017; 69:752.</a></li><li><a class="nounderline abstract_t">Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58:1758.</a></li><li><a class="nounderline abstract_t">Foley RN, Guo H, Snyder JJ, et al. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 2004; 15:1038.</a></li><li><a class="nounderline abstract_t">Khan IH, Catto GR. Long-term complications of dialysis: infection. Kidney Int Suppl 1993; 41:S143.</a></li><li><a class="nounderline abstract_t">Alexander D, Peacock E. Drug resistant organisms and their implications for the outpatient dialysis setting. Nephrol News Issues 1997; 11:27.</a></li><li><a class="nounderline abstract_t">Calfee DP. Multidrug-resistant organisms within the dialysis population: a potentially preventable perfect storm. Am J Kidney Dis 2015; 65:3.</a></li><li><a class="nounderline abstract_t">Mc Causland FR, Brunelli SM, Waikar SS. Association of smoking with cardiovascular and infection-related morbidity and mortality in chronic hemodialysis. Clin J Am Soc Nephrol 2012; 7:1827.</a></li><li><a class="nounderline abstract_t">Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int 2006; 70:1135.</a></li><li><a class="nounderline abstract_t">Sibbel S, Sato R, Hunt A, et al. The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study. BMC Nephrol 2016; 17:199.</a></li><li><a class="nounderline abstract_t">James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54:24.</a></li><li><a class="nounderline abstract_t">Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients--the United States Renal Data System. Nephrol Dial Transplant 2008; 23:680.</a></li><li><a class="nounderline abstract_t">Chen CH, Hsu WH, Chen HJ, et al. Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease. Chest 2007; 132:532.</a></li><li><a class="nounderline abstract_t">Hsu CH, Hsu CL, Shiu YN, et al. Risks of central nervous system infections and related mortality in patients undergoing dialysis. Semin Dial 2022; 35:317.</a></li><li><a class="nounderline abstract_t">Lerner PI. Meningitis caused by Streptococcus in adults. J Infect Dis 1975; 131 Suppl:S9.</a></li><li><a class="nounderline abstract_t">Mansoor GA, Ornt DB. Cryptococcal peritonitis in peritoneal dialysis patients: a case report. Clin Nephrol 1994; 41:230.</a></li><li><a class="nounderline abstract_t">Smith JW, Arnold WC. Cryptococcal peritonitis in patients on peritoneal dialysis. Am J Kidney Dis 1988; 11:430.</a></li><li><a class="nounderline abstract_t">Yinnon AM, Solages A, Treanor JJ. Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993; 17:736.</a></li><li><a class="nounderline abstract_t">McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364.</a></li><li><a class="nounderline abstract_t">Kuo CC, Lee CT, Lee IM, et al. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis 2012; 59:428.</a></li><li><a class="nounderline abstract_t">Wu MY, Hsu YH, Su CL, et al. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis 2012; 60:548.</a></li><li><a class="nounderline abstract_t">Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation. Am J Kidney Dis 2020; 75:417.</a></li><li><a class="nounderline abstract_t">Polo JR, Luño J, Menarguez C, et al. Peritoneal mucormycosis in a patient receiving continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1989; 13:237.</a></li><li><a class="nounderline abstract_t">Kang HJ, Ahn JH. The frequencies of disease entities that cause acute abdominal pain in end-stage renal disease: focused on differences between hemodialysis and peritoneal dialysis patients. The Journal of the Korean Society of Emergency Medicine 2020; 31:371.</a></li><li><a class="nounderline abstract_t">Hojs R. Cholecystolithiasis in patients with end-stage renal disease treated with haemodialysis: a study of prevalence. Am J Nephrol 1995; 15:15.</a></li><li><a class="nounderline abstract_t">Mirza MM, Wall BM. Emphysematous cholecystitis in a CAPD patient. Perit Dial Int 1997; 17:305.</a></li><li><a class="nounderline abstract_t">Ishikawa I, Chikamoto E, Nakamura M, et al. High incidence of common bile duct dilatation in autosomal dominant polycystic kidney disease patients. Am J Kidney Dis 1996; 27:321.</a></li><li><a class="nounderline abstract_t">Harwell CM, Newman LN, Cacho CP, et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int 1997; 17:586.</a></li><li><a class="nounderline abstract_t">Pakfetrat M, Malekmakan L, Roozbeh J, et al. Endoscopic findings in hemodialysis patients upon workup for kidney transplantation. Saudi J Kidney Dis Transpl 2020; 31:388.</a></li><li><a class="nounderline abstract_t">Alhoufie ST, Ibrahim NA, Alhhazmi AA, et al. Acute Helicobacter pylori Infection Prevalence Among Renal Failure Patients and Its Potential Roles with Other Chronic Diseases: A Retrospective Cohort Study. Infect Drug Resist 2022; 15:6589.</a></li><li><a class="nounderline abstract_t">Moran-Atkin E, Stem M, Lidor AO. Surgery for diverticulitis is associated with high risk of in-hospital mortality and morbidity in older patients with end-stage renal disease. Surgery 2014; 156:361.</a></li><li><a class="nounderline abstract_t">Elfanagely YM, Tanzer JR, Shobayo A, et al. Prevalence and trends of Clostridioides difficile infection among persons requiring maintenance hemodialysis: A systematic review and meta-analysis. Infect Control Hosp Epidemiol 2023; 44:1068.</a></li><li><a class="nounderline abstract_t">Bárány P, Stenvinkel P, Nord CE, Bergström J. Clostridium difficile infection--a poor prognostic sign in uremic patients? Clin Nephrol 1992; 38:53.</a></li><li><a class="nounderline abstract_t">Furuya-Kanamori L, Clements AC, Foster NF, et al. Asymptomatic Clostridium difficile colonization in two Australian tertiary hospitals, 2012-2014: prospective, repeated cross-sectional study. Clin Microbiol Infect 2017; 23:48.e1.</a></li><li><a class="nounderline abstract_t">Cunney RJ, Magee C, McNamara E, et al. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant 1998; 13:2842.</a></li><li><a class="nounderline abstract_t">Eddi R, Malik MN, Shakov R, et al. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton) 2010; 15:471.</a></li><li><a class="nounderline abstract_t">Ramesh MS, Yee J. Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease. Adv Chronic Kidney Dis 2019; 26:30.</a></li><li><a class="nounderline abstract_t">Keddis MT, Khanna S, Noheria A, et al. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc 2012; 87:1046.</a></li><li><a class="nounderline abstract_t">Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, et al. Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis. Int J Clin Pract 2015; 69:998.</a></li><li><a class="nounderline abstract_t">Tirath A, Tadros S, Coffin SL, et al. Clostridium difficile infection in dialysis patients. J Investig Med 2017; 65:353.</a></li><li><a class="nounderline abstract_t">Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.</a></li><li class="breakAll">Gilbert DN, Moellering RC, Sande MA. Table 17. In: The Sanford Guide to Antimicrobial therapy, 28th ed., Sanford, 1998. p.117.</li><li><a class="nounderline abstract_t">D'Agata EM, Mount DB, Thayer V, Schaffner W. Hospital-acquired infections among chronic hemodialysis patients. Am J Kidney Dis 2000; 35:1083.</a></li><li><a class="nounderline abstract_t">Cabaluna CC, Gary NE, Eisinger RP. Urinalysis in patients on chronic hemodialysis. Urology 1977; 10:103.</a></li><li><a class="nounderline abstract_t">Chaudhry A, Stone WJ, Breyer JA. Occurrence of pyuria and bacteriuria in asymptomatic hemodialysis patients. Am J Kidney Dis 1993; 21:180.</a></li><li><a class="nounderline abstract_t">Eisinger RP, Asghar F, Kolasa C, Weinstein MP. Does pyuria indicate infection in asymptomatic dialysis patients? Clin Nephrol 1997; 47:50.</a></li><li><a class="nounderline abstract_t">Orłowska A, Majdan M, Kozioł-Montewka M, et al. Asymptomatic bacteriuria in patients on continuous ambulatory peritoneal dialysis. Ann Univ Mariae Curie Sklodowska Med 2002; 57:285.</a></li><li><a class="nounderline abstract_t">Fasolo LR, Rocha LM, Campbell S, Peixoto AJ. Diagnostic relevance of pyuria in dialysis patients. Kidney Int 2006; 70:2035.</a></li><li><a class="nounderline abstract_t">Kwon YE, Oh DJ, Kim MJ, Choi HM. Prevalence and Clinical Characteristics of Asymptomatic Pyuria in Chronic Kidney Disease. Ann Lab Med 2020; 40:238.</a></li><li><a class="nounderline abstract_t">Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7:978.</a></li><li><a class="nounderline abstract_t">Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis 2015; 66:133.</a></li><li class="breakAll">2014 - 2019 Surveillance Summary of Bloodstream Infections in Outpatient Hemodialysis Facilities — National Healthcare Safety Network. Centers for Disease Control. Available at: https://www.cdc.gov/dialysis/pdfs/BSI-NHSN-2014to2019-508.pdf.</li><li><a class="nounderline abstract_t">Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989; 320:1188.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients--United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:197.</a></li><li><a class="nounderline abstract_t">Hadley AC, Karchmer TB, Russell GB, et al. The prevalence of resistant bacterial colonization in chronic hemodialysis patients. Am J Nephrol 2007; 27:352.</a></li><li><a class="nounderline abstract_t">Holley JL, Bernardini J, Johnston JR, Piraino B. Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program. Am J Kidney Dis 1990; 16:142.</a></li><li><a class="nounderline abstract_t">Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996; 156:1458.</a></li><li><a class="nounderline abstract_t">Roghmann MC, Fink JC, Polish L, et al. Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney Dis 1998; 32:254.</a></li><li><a class="nounderline abstract_t">Zacharioudakis IM, Zervou FN, Ziakas PD, et al. Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance. Am J Kidney Dis 2015; 65:88.</a></li><li><a class="nounderline abstract_t">Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16:105.</a></li><li class="breakAll">Medical Review Board Workgroup on VRE. Reducing the spread of vancomycin-resistant enterococcus in the dialysis setting. Mid-Atlantic Renal Coalition, 1996 Report.</li><li><a class="nounderline abstract_t">Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.</a></li><li><a class="nounderline abstract_t">Okada RC, Barry PM, Skarbinski J, Chitnis AS. Epidemiology, detection, and management of tuberculosis among end-stage renal disease patients. Infect Control Hosp Epidemiol 2018; 39:1367.</a></li><li><a class="nounderline abstract_t">Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron 1996; 73:421.</a></li><li><a class="nounderline abstract_t">Taskapan H, Utas C, Oymak FS, et al. The outcome of tuberculosis in patients on chronic hemodialysis. Clin Nephrol 2000; 54:134.</a></li><li><a class="nounderline abstract_t">Lui SL, Tang S, Li FK, et al. Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2001; 38:1055.</a></li><li><a class="nounderline abstract_t">Yen YF, Feng JY, Pan SW, et al. Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study. Epidemiol Infect 2017; 145:1374.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Tuberculosis transmission in a renal dialysis center--Nevada, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:873.</a></li><li><a class="nounderline abstract_t">Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the kidney. J Am Soc Nephrol 2001; 12:1307.</a></li><li><a class="nounderline abstract_t">Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16:38.</a></li><li><a class="nounderline abstract_t">Hung KH, Lee CT, Chen JB, Hsu KT. Tuberculous peritonitis in uremic patients. Clin Nephrol 2003; 60:113.</a></li><li><a class="nounderline abstract_t">Kriki P, Thodis E, Deftereos S, et al. A tumor-like manifestation of extrapulmonary tuberculosis in a hemodialysis patient. Clin Nephrol 2009; 71:714.</a></li><li><a class="nounderline abstract_t">Smirnoff M, Patt C, Seckler B, Adler JJ. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998; 113:25.</a></li><li><a class="nounderline abstract_t">Woeltje KF, Mathew A, Rothstein M, et al. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998; 31:848.</a></li><li><a class="nounderline abstract_t">Korzets A, Gafter U. Tuberculosis prophylaxis for the chronically dialysed patient--yes or no? Nephrol Dial Transplant 1999; 14:2857.</a></li><li><a class="nounderline abstract_t">Poduval RD, Hammes MD. Tuberculosis screening in dialysis patients--is the tuberculin test effective? Clin Nephrol 2003; 59:436.</a></li><li><a class="nounderline abstract_t">Wauters A, Peetermans WE, Van den Brande P, et al. The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant 2004; 19:433.</a></li><li><a class="nounderline abstract_t">Eleftheriadis T, Tsiaga P, Antoniadi G, et al. The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients. Am J Kidney Dis 2005; 46:706.</a></li><li><a class="nounderline abstract_t">Cahuayme-Zuniga LJ, Brust KB. Mycobacterial Infections in Patients With Chronic Kidney Disease and Kidney Transplantation. Adv Chronic Kidney Dis 2019; 26:35.</a></li></ol></div><div id="topicVersionRevision">Topic 1893 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : United States Renal Data System</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : United States Renal Data System</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : United States Renal Data System</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : United States Renal Data System</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : United States Renal Data System</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815225" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Infectious complications in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21906862" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The risk of infection-related hospitalization with decreased kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116291" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : UK Renal Registry 18th Annual Report: Chapter 12 Epidemiology of Reported Infections amongst Patients Receiving Dialysis for Established Renal Failure in England 2013 to 2014: a Joint Report from Public Health England and the UK Renal Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178234" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical epidemiology of infectious disease among patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27884474" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : CKD and Risk for Hospitalization With Infection: The Atherosclerosis Risk in Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012910" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mortality caused by sepsis in patients with end-stage renal disease compared with the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034107" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Septicemia in the United States dialysis population, 1991 to 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320909" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-term complications of dialysis: infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391388" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Drug resistant organisms and their implications for the outpatient dialysis setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25523798" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multidrug-resistant organisms within the dialysis population: a potentially preventable perfect storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22917700" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association of smoking with cardiovascular and infection-related morbidity and mortality in chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871243" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27955633" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447535" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : CKD and risk of hospitalization and death with pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029368" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pneumonia in incident dialysis patients--the United States Renal Data System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699132" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107185" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risks of central nervous system infections and related mortality in patients undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1092775" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Meningitis caused by Streptococcus in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8026116" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cryptococcal peritonitis in peritoneal dialysis patients: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285671" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cryptococcal peritonitis in patients on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8268358" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368499" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178678" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22575666" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of herpes zoster in CKD: a matched-cohort study based on administrative data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31585683" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919604" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Peritoneal mucormycosis in a patient receiving continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The frequencies of disease entities that cause acute abdominal pain in end-stage renal disease: focused on differences between hemodialysis and peritoneal dialysis patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872359" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cholecystolithiasis in patients with end-stage renal disease treated with haemodialysis: a study of prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237295" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Emphysematous cholecystitis in a CAPD patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604699" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High incidence of common bile duct dilatation in autosomal dominant polycystic kidney disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655159" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32394911" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Endoscopic findings in hemodialysis patients upon workup for kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36386419" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute Helicobacter pylori Infection Prevalence Among Renal Failure Patients and Its Potential Roles with Other Chronic Diseases: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24957670" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Surgery for diverticulitis is associated with high risk of in-hospital mortality and morbidity in older patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36148878" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prevalence and trends of Clostridioides difficile infection among persons requiring maintenance hemodialysis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1499170" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clostridium difficile infection--a poor prognostic sign in uremic patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27615716" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Asymptomatic Clostridium difficile colonization in two Australian tertiary hospitals, 2012-2014: prospective, repeated cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9829488" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clostridium difficile colitis associated with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609100" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chronic kidney disease as a risk factor for Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30876614" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127731" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clostridium difficile infection in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26147121" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737913" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clostridium difficile infection in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8043060" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clostridium difficile colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8043060" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clostridium difficile colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845821" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hospital-acquired infections among chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/898446" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Urinalysis in patients on chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8430679" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Occurrence of pyuria and bacteriuria in asymptomatic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021242" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Does pyuria indicate infection in asymptomatic dialysis patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12898851" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Asymptomatic bacteriuria in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16883321" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnostic relevance of pyuria in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31858764" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevalence and Clinical Characteristics of Asymptomatic Pyuria in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8829111" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Calciphylaxis in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25960299" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Calciphylaxis: risk factors, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25960299" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Calciphylaxis: risk factors, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2651925" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17347644" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients--United States, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541264" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The prevalence of resistant bacterial colonization in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2382651" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678715" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bloodstream infections with vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708609" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042816" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7759811" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Recommendations for preventing the spread of vancomycin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7759811" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Recommendations for preventing the spread of vancomycin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16323094" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30231948" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Epidemiology, detection, and management of tuberculosis among end-stage renal disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8832601" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Increased incidence of tuberculosis in patients undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968689" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The outcome of tuberculosis in patients on chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684559" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28190404" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385919" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tuberculosis transmission in a renal dialysis center--Nevada, 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11373356" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Tuberculosis and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535299" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Tuberculosis and chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940613" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Tuberculous peritonitis in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473642" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A tumor-like manifestation of extrapulmonary tuberculosis in a hemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440563" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Tuberculin and anergy skin testing of patients receiving long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9590196" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Tuberculosis infection and anergy in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10570088" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tuberculosis prophylaxis for the chronically dialysed patient--yes or no?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12834175" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tuberculosis screening in dialysis patients--is the tuberculin test effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736970" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The value of tuberculin skin testing in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183426" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30876615" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Mycobacterial Infections in Patients With Chronic Kidney Disease and Kidney Transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
